Related Experiment Video
Updated: Feb 3, 2026
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
14.2K
[Risk-adapted (immuno)therapy for renal cell carcinoma]
1Schwerpunkt Interdisziplinäre Uroonkologie am Westdeutschen Tumorzentrum, Universitätsklinikum Essen, Hufelandstr. 55, 45147, Essen, Deutschland. viktor.gruenwald@uk-essen.de.
Der Urologe. Ausg. A
|October 24, 2018
Summary
Immunotherapy and new tyrosine kinase inhibitors (TKIs) are expanding treatment options for metastatic renal cell carcinoma (mRCC). Optimizing risk-adapted therapies is crucial for balancing efficacy and safety in mRCC treatment.
Area of Science:
- Oncology
- Medical Therapeutics
Background:
- Metastatic renal cell carcinoma (mRCC) treatment landscape is evolving with new therapeutic strategies.
- Immunotherapy and targeted therapies represent key advancements in mRCC management.
Purpose of the Study:
- To review the current therapeutic landscape for metastatic renal cell carcinoma (mRCC).
- To discuss the integration of immunotherapy and novel tyrosine kinase inhibitors (TKIs) in mRCC treatment algorithms.
- To highlight the importance of risk-adapted therapy in optimizing patient outcomes.
Main Methods:
- Review of recent clinical trials and therapeutic guidelines for mRCC.
- Analysis of the efficacy and safety profiles of emerging treatments.
- Discussion of treatment strategies balancing efficacy and toxicity.
Main Results:
- Immunotherapy offers a new therapeutic axis for mRCC, complementing targeted therapies.
- New tyrosine kinase inhibitors (TKIs) like cabozantinib and tivozanib are improving targeted therapy effectiveness.
- While immune checkpoint blockade is clinically important, specific combinations await approval.
Conclusions:
- The integration of immunotherapy and novel TKIs is redefining first-line treatment for mRCC.
- Risk-adapted therapeutic approaches are essential for optimizing individual patient care in mRCC.
- Balancing treatment efficacy with potential risks is paramount for successful mRCC management.
More Related Videos
Related Concept Videos
01:30Continuous Renal Replacement Therapy
1.0K
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
1.0K
01:26Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy
217
Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
217
02:53Adaptive Mechanisms in Cancer Cells
7.1K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.1K
01:23Cells of the Adaptive Immune Response
8.9K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
8.9K
01:12Relative Risk
2.1K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.1K
00:59Gene Therapy
27.6K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.6K